A naturally occurring variant of the human prion protein completely prevents prion disease

  • Nature volume 522, pages 478481 (25 June 2015)
  • doi:10.1038/nature14510
  • Download Citation


Mammalian prions, transmissible agents causing lethal neurodegenerative diseases, are composed of assemblies of misfolded cellular prion protein (PrP)1. A novel PrP variant, G127V, was under positive evolutionary selection during the epidemic of kuru—an acquired prion disease epidemic of the Fore population in Papua New Guinea—and appeared to provide strong protection against disease in the heterozygous state2. Here we have investigated the protective role of this variant and its interaction with the common, worldwide M129V PrP polymorphism. V127 was seen exclusively on a M129 PRNP allele. We demonstrate that transgenic mice expressing both variant and wild-type human PrP are completely resistant to both kuru and classical Creutzfeldt–Jakob disease (CJD) prions (which are closely similar) but can be infected with variant CJD prions, a human prion strain resulting from exposure to bovine spongiform encephalopathy prions to which the Fore were not exposed. Notably, mice expressing only PrP V127 were completely resistant to all prion strains, demonstrating a different molecular mechanism to M129V, which provides its relative protection against classical CJD and kuru in the heterozygous state. Indeed, this single amino acid substitution (G→V) at a residue invariant in vertebrate evolution is as protective as deletion of the protein. Further study in transgenic mice expressing different ratios of variant and wild-type PrP indicates that not only is PrP V127 completely refractory to prion conversion but acts as a potent dose-dependent inhibitor of wild-type prion propagation.

  • Subscribe to Nature for full access:



Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.


  1. 1.

    Prion diseases of humans and animals: their causes and molecular basis. Annu. Rev. Neurosci. 24, 519–550 (2001).

  2. 2.

    et al. A novel protective prion protein variant that colocalizes with kuru exposure. N. Engl. J. Med. 361, 2056–2065 (2009).

  3. 3.

    & Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501, 45–51 (2013).

  4. 4.

    , & Genetic predisposition to iatrogenic Creutzfeldt-Jakob disease. Lancet 337, 1441–1442 (1991).

  5. 5.

    , , & Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease. Nature 352, 340–342 (1991).

  6. 6.

    Molecular neurology of prion disease. J. Neurol. Neurosurg. Psychiatry 76, 906–919 (2005).

  7. 7.

    et al. Balancing selection at the prion protein gene consistent with prehistoric kuru-like epidemics. Science 300, 640–643 (2003).

  8. 8.

    et al. Crystal structure of human prion protein bound to a therapeutic antibody. Proc. Natl Acad. Sci. USA 106, 2554–2558 (2009).

  9. 9.

    Variant Creutzfeldt-Jakob disease. Lancet 354, 317–323 (1999).

  10. 10.

    & A general model of prion strains and their pathogenicity. Science 318, 930–936 (2007).

  11. 11.

    , , , & Protective prion protein polymorphisms against sporadic Creutzfeldt-Jakob disease. Lancet 351, 419 (1998).

  12. 12.

    et al. BSE prions propagate as either variant CJD-like or sporadic CJD-like prion strains in transgenic mice expressing human prion protein. EMBO J. 21, 6358–6366 (2002).

  13. 13.

    , , , & Pathogenic human prion protein rescues PrP null phenotype in transgenic mice. Neurosci. Lett. 360, 33–36 (2004).

  14. 14.

    et al. Human prion protein with valine 129 prevents expression of variant CJD phenotype. Science 306, 1793–1796 (2004).

  15. 15.

    , & Contribution of transgenic models to understanding human prion disease. Neuropathol. Appl. Neurobiol. 36, 576–597 (2010).

  16. 16.

    et al. Unaltered susceptibility to BSE in transgenic mice expressing human prion protein. Nature 378, 779–783 (1995).

  17. 17.

    et al. The same prion strain causes vCJD and BSE. Nature 389, 448–450 (1997).

  18. 18.

    et al. Dissociation of pathological and molecular phenotype of variant Creutzfeldt-Jakob disease in transgenic human prion protein 129 heterozygous mice. Proc. Natl Acad. Sci. USA 103, 10759–10764 (2006).

  19. 19.

    et al. Kuru prions and sporadic Creutzfeldt-Jakob disease prions have equivalent transmission properties in transgenic and wild-type mice. Proc. Natl Acad. Sci. USA 105, 3885–3890 (2008).

  20. 20.

    , , , & Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD. Nature 383, 685–690 (1996).

  21. 21.

    et al. Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature 389, 498–501 (1997).

  22. 22.

    et al. Dominant-negative inhibition of prion replication in transgenic mice. Proc. Natl Acad. Sci. USA 99, 13079–13084 (2002).

  23. 23.

    et al. Human prion protein (PrP) 219K is converted to PrPSc but shows heterozygous inhibition in variant Creutzfeldt-Jakob disease infection. J. Biol. Chem. 284, 3603–3609 (2009).

  24. 24.

    , , , & Strain specific resistance to murine scrapie associated with a naturally occurring human prion protein polymorphism at residue 171. PLoS Pathog. 7, e1002275 (2011).

  25. 25.

    , , & Dominant prion mutants induce curing through pathways that promote chaperone-mediated disaggregation. Nature Struct. Mol. Biol. 18, 486–492 (2011).

  26. 26.

    et al. Mice devoid of PrP are resistant to scrapie. Cell 73, 1339–1347 (1993).

  27. 27.

    The epidemiology of kuru: monitoring the epidemic from its peak to its end. Phil. Trans. R. Soc. Lond. B 363, 3707–3713 (2008).

  28. 28.

    et al. Molecular classification of sporadic Creutzfeldt-Jakob disease. Brain 126, 1333–1346 (2003).

  29. 29.

    et al. Absence of spontaneous disease and comparative prion susceptibility of transgenic mice expressing mutant human prion proteins. J. Gen. Virol. 90, 546–558 (2009).

  30. 30.

    et al. Molecular diagnosis of human prion disease. Methods Mol. Biol. 459, 197–227 (2008).

Download references


This work was funded by the UK Medical Research Council. We thank all staff at our Biological Services Facility for animal care; C. O’Malley and S. Lyall for technical support with histology; and R. Newton and R. Young for preparation of figures. We thank patients and families for consent to use human tissues. We thank UK neurological and neuropathology colleagues for providing brain tissue from CJD patients. Some of this work was undertaken at University College London Hospitals/University College London, which received a proportion of funding from the Department of Health's National Institute for Health Research Biomedical Research Centres funding scheme. We thank the Fore communities and P. Siba and colleagues at the Papua New Guinea Institute of Medical Research for their long-term support. We thank the late C. Gajdusek, the late J. Gibbs, S. Landis, and their associates from the Laboratory of Central Nervous System Studies of the National Institutes of Health, Bethesda, USA, for archiving and sharing kuru samples.

Author information

Author notes

    • Richard Houghton

    Present address: Strangeways Research Laboratory, Worts’ Causeway, Cambridge CB8 8UX, UK


  1. MRC Prion Unit, Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG, UK

    • Emmanuel A. Asante
    • , Michelle Smidak
    • , Andrew Grimshaw
    • , Richard Houghton
    • , Andrew Tomlinson
    • , Asif Jeelani
    • , Tatiana Jakubcova
    • , Shyma Hamdan
    • , Angela Richard-Londt
    • , Jacqueline M. Linehan
    • , Sebastian Brandner
    • , Michael Alpers
    • , Jerome Whitfield
    • , Simon Mead
    • , Jonathan D. F. Wadsworth
    •  & John Collinge
  2. Papua New Guinea Institute of Medical Research, Goroka, Eastern Highlands Province, Papua New Guinea

    • Michael Alpers
    •  & Jerome Whitfield


  1. Search for Emmanuel A. Asante in:

  2. Search for Michelle Smidak in:

  3. Search for Andrew Grimshaw in:

  4. Search for Richard Houghton in:

  5. Search for Andrew Tomlinson in:

  6. Search for Asif Jeelani in:

  7. Search for Tatiana Jakubcova in:

  8. Search for Shyma Hamdan in:

  9. Search for Angela Richard-Londt in:

  10. Search for Jacqueline M. Linehan in:

  11. Search for Sebastian Brandner in:

  12. Search for Michael Alpers in:

  13. Search for Jerome Whitfield in:

  14. Search for Simon Mead in:

  15. Search for Jonathan D. F. Wadsworth in:

  16. Search for John Collinge in:


E.A.A., J.D.F.W. and J.C. conceived and designed the study. M.S. and E.A.A. cloned the transgene constructs. R.H., A.T. and A.J. generated and developed transgenic lines. M.S., T.J., S.H. and E.A.A. analysed and characterized the transgenic mice. A.G. analysed prion-infected mouse brains by immunoblotting. A.R.-L., J.M.L. and S.B. performed histological analyses and interpreted the pathology data. S.M., J.W., J.D.F.W. and M.A. characterized CJD cases and inocula. E.A.A. supervised the study and collated data. E.A.A., J.D.F.W. and J.C. drafted the paper with contributions from all authors.

Competing interests

J.C. is a Director and J.C. and J.D.F.W. are shareholders of D-Gen Limited, an academic spin-out company in the field of prion diagnosis, decontamination and therapy. D-Gen supplied the ICSM 35 antibody used in this study.

Corresponding author

Correspondence to John Collinge.

Extended data


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.